HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on BioLine Rx (NASDAQ:BLRX) and maintains a $21 price target.
March 26, 2024 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on BioLine Rx with a $21 price target.
The reiteration of a Buy rating and a maintained price target of $21 by a reputable analyst suggests a strong bullish sentiment towards BioLine Rx. This endorsement could positively influence investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100